Company: TVRD
Filing Date: 2025-10-07
Form Type: S-1/A
Source: 0001104659-25-097519
Chunk: 273

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-07
Form: S-1/A
Chunk 273
---
,250,032 | ​ | 19,999,996.91 |
| Entities affiliated with Sporos(3)     | ​ | 4,684,679 | ​ | 17,077,031.89 |
| David J. Tweardy                       | ​ |    53,695 | ​ |    163,643.82 |
| Entities affiliated with Palkon(4)     | ​ | 3,274,707 | ​ | 12,474,996.33 |
| Shaheen Wirk(5)                        | ​ |    31,252 | ​ |    105,830.12 |
| BioMatrix Partners Ltd.(6)             |   |   173,448 |   |    528,602.73 |

| (1) | Additional details regarding these stockholders and their equity holdings are included in this prospectus under the section titled “Principal Securityholders” |

| (2) | Consisted of (i) 4,662,044 shares of Series B Preferred Stock held by Slate Path Master Fund LP and (ii) 587,988 shares of Series B Preferred Stock held by SPB Master Fund LP. Jamie McNab was a member of Legacy Tvardi’s board of directors and a Partner of Slate Path Capital LP, which is the investment manager of Slate Path Master Fund LP and SPB Master Fund LP. Mr. McNab may be deemed to share the power to direct the disposition and vote of the shares held by Slate Path, but disclaims beneficial ownership of all shares held by Slate Path except to any pecuniary interest therein. |

| (3) | Consisted of (i) 3,450,397 shares of Series B Preferred Stock held by Sporos Bioventures LLC and (ii) 1,234,282 shares of Series B Preferred Stock held by Sporos Co-Invest T1 LLC (together with Sporos Bioventures LLC and other affiliates, “Sporos”). |

| (4) | Consisted of (i) 1,312,508 shares of common stock issuable upon the conversion of Series B Preferred Stock held by Palkon Holdings, LLC and (ii) 1,962,199 of common stock issuable upon the conversion of Series B Preferred Stock held by Palkon TT |

160

| Holdings, LLC. Palkon GP, LLC is the Manager of Palkon TT Holdings, LLC and the general partner